Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Ticagrelor Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel catalytic transfer hydrogenation method for Ticagrelor intermediate. Reduces cost and toxicity compared to borane reduction. High ee value.
Novel enzyme mutant enables high-purity drug intermediate synthesis with improved conversion rates and industrial scalability for global supply chains.
Discover advanced biocatalytic synthesis for ticagrelor intermediates using engineered ketoreductase. Achieve high substrate loading and cost reduction in pharmaceutical manufacturing.
Novel azide ring-opening route for Ticagrelor Intermediate C. Reduces steps, improves purity, ensures supply chain stability for API manufacturing.
Novel three-step synthesis avoids palladium carbon and lithium borohydride. Reduces cost and complexity for high-purity pharmaceutical intermediate manufacturing.
Novel five-step route for Ticagrelor intermediate V reduces cost and improves yield for pharmaceutical supply chains globally ensuring high purity and reliability.
Patent CN104520278A reveals a robust synthesis for Ticagrelor intermediates, offering cost reduction in API manufacturing and enhanced supply chain reliability for global buyers.
Novel dioxolane route eliminates palladium hydrogenation ensuring high purity and cost reduction in pharmaceutical intermediates manufacturing for global supply chains.
Novel organosilane reduction method for Ticagrelor intermediate ensures high purity and supply chain stability for global pharmaceutical manufacturing partners.
Novel green synthesis of 4,6-dichloro-2-(propylthio)-5-aminopyrimidine avoiding hazardous diazotization. Cost-effective API intermediate manufacturing solution.
Patent CN115109759B reveals novel LsCR mutants for chiral alcohol synthesis. Achieve superior stability and yield for reliable pharmaceutical intermediate supply chains.
Patent CN103923020A reveals a cost-effective synthesis route for Ticagrelor intermediates. Enhance supply chain reliability and reduce manufacturing costs with optimized chemistry.
Patent CN107573333B reveals a novel Ticagrelor intermediate synthesis. Offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN110981883B reveals a superior 2-step synthesis for Ticagrelor intermediates. Discover cost-effective manufacturing and reliable supply chain solutions for API production.
Patent CN115011573B enables efficient synthesis of chiral alcohols with high substrate loading and reduced cofactor costs for pharmaceutical supply chains.
Patent CN103936767B details high-yield synthesis for Ticagrelor intermediates. Offers scalable, cost-effective manufacturing solutions for global pharmaceutical supply chains.
Novel KRED enzyme process for ticagrelor intermediate. High selectivity, mild conditions, cost-effective supply chain solution for pharma manufacturing.
Novel Boc-protection route eliminates palladium hydrogenation. Reduces cost and complexity for ticagrelor intermediate manufacturing. Reliable supply chain partner.
Patent CN111575334B reveals a stable immobilized enzyme method for synthesizing chiral alcohols, offering significant cost reduction and supply reliability for API manufacturing.
Novel route for ticagrelor five-membered ring intermediate improves atom economy and reduces waste for reliable pharmaceutical intermediate suppliers.